Rally Kid Rocco, Beating Blood Cancer


The most common type of blood cancer in children is leukemia. Leukemia has two different types: Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). ALL is the most common diagnosis of children with cancer. When a child has leukemia, their immune blood cells do not work properly and the sick blood cells push out the healthy blood cells.

Lymphoma, another type of blood cancer, is a cancer of the immune system and the lymphocytes. The two types of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma. With lymphoma, the infected cells do not properly protect the body and they push out the healthy cells.


Rally Funded Blood Cancer Research

Dr. Mark Levis
Johns Hopkins University
Targeted therapy on AML patients

Dr. Kevin Bunting
Emory University
Targeting STAT5-induced metabolic reprogramming for pediatric AML therapy

Dr. Donald Small
Johns Hopkins University, School of Medicine
Developing Molecularly Targeted Therapy for FLT3 Mutant Pediatric AML

Leukemia and Lymphoma Society
Beat AML

Children’s Oncology Group
Improved Care for ALL Relapsing Patients

Dr. Nicole Anderson
Dana-Farber Cancer Institute
Utilizing Zebrafish to identify new targeted therapies for ETP-ALL

Dr. Michael Burke
Medical College of Wisconsin
Pilot Study of Decitabine and Vorinostat with Chemotherapy in Relapse ALL

Dr. Peiyun Chang
Stanford University
Mixed Lineage Leukemia 2nd Year Research

Dr. Tiffany Chang
University of California, San Francisco
Targeted Therapeutics for Juvenile Myelomonocytic Leukemia

Dr. John Crispino
Northwestern University-Chicago Campus
Biology and Targeted Therapy for Down’s Syndrome-ALL Connection
DYRK1A is a novel target in B-cell leukemia

Dr. Todd Druley
Washington University
Rare Genetic Factors for ALL–Partnered with Hope street Kids

Dr. Adolfo Ferrando
Columbia University Medical Center
Fund research in generation and characterization of a preclinical model of human T-ALL

Dr. Rebecca Gardner
Seattle Children’s Hospital
Autologous T cells modified to target CD19+ Pediatric ALL

Dr. Paul Gaynon
Children’s Hospital of Los Angeles
Lab testing for twelve patients enrolled in a new study of a drug to treat relapsed ALL similar to one in use that is not always effective and to which some patients are allergic

Dr. Kay Koehler
Developing Novel Therapies for Pediatric and Young Adult ALL

Dr. Loretta Li
Dana-Farber Cancer Institute
Identifying Mechanisms of Resistance to Type II JAK2 Inhibitors in B-ALL

Dr. Arianne Perez-Garcia
Columbia University Medical Center
The role of RUNX1 in T-ALL

Dr. Marta Sanchez-Martin
Columbia University Medical Center
New synergistic drug combinations for the treatment of T-ALL

Dr. Sarah Tasian
Children’s Hospital of Philadelphia
PI3K Signaling Therapeutics for Childhood ALL

Dr. Scott Armstrong
Children’s Hospital of Boston
Study genetic mechanisms responsible for drug-resistance in leukemia

Dr. Mark Chiang
University of Michigan
Amplification of NOTCH1 signals by ZMIZ1 in T-cell leukemia
Direct and selective coregulation of Notch1 by Zmiz1 in T-cell leukemia

Dr. Daniel Lacorazza
Baylor College of Medicine
Treatment of Acute Lymphoblastic Leukemia with a natural product

Dr. Elena Ladas
Columbia University Medical Center
Dietary Intake and Obesity in Children with Acute Lymphoblastic Leukemia

Dr. Linda Resar
Johns Hopkins Consortium
Targeting Novel MicroRNA-mRNA Pathways in Relapsed Leukemia

Dr. Kevin Shannon
University of California, San Francisco
Response & Resistance to Targeted & Conventional Agents in Myeloid Leukemia

Dr. Dave Utpal
Vanderbilt University Medical Center
Identification of Genes Cooperating with LM02 in T-cell Leukemia

Dr. Agnieszka Wendorff
Columbia University Medical Center
The role of PHF6 in leukemia stem cell self-renewal

Dr. Lisa Giulino
Memorial-Sloan Kettering Cancer Center
Molecular Characterization of Pediatric Burkitt Lymphoma

Dr. Ann Haight
Aflac/Children’s Healthcare of Atlanta
Continued Growth and Support of the Pediatric Blood and Marrow Transplant Program

Rally Kids Fighting Blood Cancer